Access the full text.
Sign up today, get DeepDyve free for 14 days.
Y. Zarate, R. Hopkin (2008)
Fabry's diseaseThe Lancet, 372
R. Vijapurapu, S. Nordin, S. Baig, Boyang Liu, S. Rosmini, J. Augusto, M. Tchan, D. Hughes, T. Geberhiwot, J. Moon, R. Steeds, R. Kozor (2018)
Global longitudinal strain, myocardial storage and hypertrophy in Fabry diseaseHeart, 105
S. Pica, D. Sado, V. Maestrini, M. Fontana, S. White, T. Treibel, G. Captur, S. Anderson, S. Piechnik, M. Robson, R. Lachmann, E. Murphy, A. Mehta, D. Hughes, P. Kellman, P. Elliott, A. Herrey, J. Moon (2014)
Reproducibility of native myocardial T1 mapping in the assessment of Fabry disease and its role in early detection of cardiac involvement by cardiovascular magnetic resonanceJournal of Cardiovascular Magnetic Resonance, 16
(2019)
International Collaborative Fabry Disease D ow nladed from http://journals.org by on D ecem er 17
A. Camporeale, M. Pieroni, F. Pieruzzi, P. Lusardi, S. Pica, M. Spada, R. Mignani, A. Burlina, F. Bandera, M. Guazzi, F. Graziani, F. Crea, A. Greĭser, S. Boveri, F. Ambrogi, M. Lombardi (2019)
Predictors of Clinical Evolution in Prehypertrophic Fabry DiseaseCirculation: Cardiovascular Imaging, 12
C. Whybra, E. Miebach, E. Mengel, A. Gal, K. Baron, M. Beck, C. Kampmann (2009)
A 4-year study of the efficacy and tolerability of enzyme replacement therapy with agalsidase alfa in 36 women with Fabry diseaseGenetics in Medicine, 11
R. Mignani, F. Pieruzzi, F. Berri, A. Burlina, B. Chinea, M. Gallieni, M. Pieroni, A. Salviati, M. Spada (2016)
FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in Fabry diseaseClinical Kidney Journal, 9
F. Weidemann, M. Niemann, F. Breunig, S. Herrmann, M. Beer, S. Störk, W. Voelker, G. Ertl, C. Wanner, J. Strotmann (2009)
Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy Evidence for a Better Outcome With Early TreatmentCirculation, 119
M. Motwani, S. Banypersad, P. Woolfson, S. Waldek (2012)
Enzyme replacement therapy improves cardiac features and severity of Fabry disease.Molecular genetics and metabolism, 107 1-2
D. Hughes, P. Elliott, J. Shah, J. Zuckerman, G. Coghlan, J. Brookes, Atul Mehta (2007)
Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfaHeart, 94
C. Kampmann, A. Linhart, F. Baehner, T. Paleček, C. Wiethoff, E. Miebach, C. Whybra, A. Gal, J. Bultas, M. Beck (2008)
Onset and progression of the Anderson-Fabry disease related cardiomyopathy.International journal of cardiology, 130 3
S. Nordin, R. Kozor, S. Baig, A. Abdel‐Gadir, K. Medina-Menacho, S. Rosmini, G. Captur, M. Tchan, T. Geberhiwot, E. Murphy, R. Lachmann, U. Ramaswami, N. Edwards, D. Hughes, R. Steeds, J. Moon (2018)
Cardiac Phenotype of Prehypertrophic Fabry DiseaseCirculation. Cardiovascular Imaging, 11
S. Nordin, R. Kozor, H. Bulluck, S. Castelletti, S. Rosmini, A. Abdel‐Gadir, S. Baig, A. Mehta, D. Hughes, J. Moon (2016)
Cardiac Fabry Disease With Late Gadolinium Enhancement Is a Chronic Inflammatory Cardiomyopathy.Journal of the American College of Cardiology, 68 15
A. Maceira, S. Prasad, Muhammad Khan, D. Pennell (2006)
Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance.Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance, 8 3
M. Arends, M. Biegstraaten, D. Hughes, A. Mehta, P. Elliott, D. Oder, O. Watkinson, F. Vaz, A. Kuilenburg, C. Wanner, C. Hollak (2017)
Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: Analysis of prognostic factorsPLoS ONE, 12
M. Ng, N. Uffon, W. Ilcox, P. Ermain, P. Ee, S. Aldek, L. Aplan, E. Inthorst, R. Esnick (2001)
SAFETY AND EFFICACY OF RECOMBINANT HUMAN a -GALACTOSIDASE A REPLACEMENT THERAPY IN FABRY'S DISEASE
S. Rombach, B. Smid, G. Linthorst, M. Dijkgraaf, C. Hollak (2014)
Natural course of Fabry disease and the effectiveness of enzyme replacement therapy: a systematic review and meta-analysisJournal of Inherited Metabolic Disease, 37
A. Frustaci, R. Verardo, C. Grande, N. Galea, P. Piselli, I. Carbone, M. Alfarano, M. Russo, C. Chimenti (2018)
Immune‐Mediated Myocarditis in Fabry Disease CardiomyopathyJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 7
C. Coats, V. Parisi, M. Ramos, K. Janagarajan, C. O’Mahony, A. Dawnay, R. Lachmann, E. Murphy, A. Mehta, D. Hughes, P. Elliott (2013)
Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease.The American journal of cardiology, 111 1
C. Kampmann, A. Perrin, M. Beck (2015)
Effectiveness of agalsidase alfa enzyme replacement in Fabry disease: cardiac outcomes after 10 years’ treatmentOrphanet Journal of Rare Diseases, 10
D. Sado, S. White, S. Piechnik, S. Banypersad, T. Treibel, G. Captur, M. Fontana, V. Maestrini, A. Flett, M. Robson, R. Lachmann, E. Murphy, A. Mehta, D. Hughes, S. Neubauer, P. Elliott, J. Moon (2013)
Identification and Assessment of Anderson-Fabry Disease by Cardiovascular Magnetic Resonance Noncontrast Myocardial T1 MappingCirculation: Cardiovascular Imaging, 6
J. Moon, B. Sachdev, A. Elkington, W. McKenna, A. Mehta, D. Pennell, Philip Leed, P. Elliott (2003)
Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.European heart journal, 24 23
K. Wyatt, W. Henley, Lindsey Anderson, Robert Anderson, V. Nikolaou, K. Stein, L. Klinger, D. Hughes, S. Waldek, R. Lachmann, A. Mehta, A. Vellodi, S. Logan (2012)
The effectiveness and cost-effectiveness of enzyme and substrate replacement therapies: a longitudinal cohort study of people with lysosomal storage disorders.Health technology assessment, 16 39
Obert, D. J., Esnick (2001)
UvA-DARE ( Digital Academic Repository ) Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry ' s disease
S. Rosmini, H. Bulluck, G. Captur, T. Treibel, A. Abdel‐Gadir, A. Bhuva, V. Culotta, A. Merghani, M. Fontana, V. Maestrini, A. Herrey, Kelvin Chow, Richard Thompson, S. Piechnik, P. Kellman, C. Manisty, J. Moon (2018)
Myocardial native T1 and extracellular volume with healthy ageing and genderEuropean Heart Journal Cardiovascular Imaging, 19
F. Weidemann, M. Niemann, S. Störk, F. Breunig, Meinrad Beer, C. Sommer, S. Herrmann, Georg Ertl, C. Wanner (2013)
Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complicationsJournal of Internal Medicine, 274
Richard Thompson, Kelvin Chow, Aneal Khan, A. Chan, M. Shanks, I. Paterson, G. Oudit (2013)
T1 Mapping With Cardiovascular MRI Is Highly Sensitive for Fabry Disease Independent of Hypertrophy and SexCirculation: Cardiovascular Imaging, 6
S. Waldek, M. Patel, M. Banikazemi, R. Lemay, P. Lee (2009)
Life expectancy and cause of death in males and females with Fabry disease: Findings from the Fabry RegistryGenetics in Medicine, 11
G. Captur, P. Gatehouse, K. Keenan, Friso Heslinga, R. Bruehl, M. Prothmann, M. Graves, R. Eames, C. Torlasco, G. Benedetti, J. Donovan, B. Ittermann, R. Boubertakh, A. Bathgate, Celine Royet, W. Pang, R. Nezafat, M. Salerno, P. Kellman, J. Moon (2016)
A medical device-grade T1 and ECV phantom for global T1 mapping quality assurance—the T1 Mapping and ECV Standardization in cardiovascular magnetic resonance (T1MES) programJournal of Cardiovascular Magnetic Resonance, 18
S. Baig, Nicky Edward, D. Kotecha, Boyang Liu, S. Nordin, R. Kozor, J. Moon, T. Geberhiwot, R. Steeds (2018)
Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practiceEP Europace, 20
S. Piechnik, V. Ferreira, A. Lewandowski, N. Ntusi, R. Banerjee, C. Holloway, M. Hofman, D. Sado, V. Maestrini, S. White, M. Lazdam, T. Karamitsos, J. Moon, S. Neubauer, P. Leeson, M. Robson (2013)
Normal variation of magnetic resonance T1 relaxation times in the human population at 1.5 T using ShMOLLIJournal of Cardiovascular Magnetic Resonance, 15
Haran Yogasundaram, A. Nikhanj, B. Putko, M. Boutin, Shailly Jain‐Ghai, Aneal Khan, C. Auray-Blais, M. West, G. Oudit (2018)
Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection FractionJournal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 7
J. Strotmann, F. Breunig, C. Wanner, F. Weidemann (2007)
Progression of Fabry cardiomyopathy.Clinical therapeutics, 29 Suppl A
S. Nordin, R. Kozor, K. Medina-Menacho, A. Abdel‐Gadir, S. Baig, D. Sado, I. Lobascio, E. Murphy, R. Lachmann, A. Mehta, N. Edwards, U. Ramaswami, R. Steeds, D. Hughes, J. Moon (2019)
Proposed Stages of Myocardial Phenotype Development in Fabry Disease.JACC. Cardiovascular imaging
Supplemental Digital Content is available in the text.
Circulation: Cardiovascular Imaging – Wolters Kluwer Health
Published: Dec 1, 2019
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.